GlassScriptPhysician profile
Laju Mathew
NPI 1235438466
$1,571.58
in general payments reported to CMS, 2019-2025
24 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $74.08 · 2021: $18.73 · 2022: $38.33 · 2023: $336 · 2024: $173 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $271.55 | 2019-2024 | Oracea |
| Janssen Biotech, INC. | $190.56 | 2022-2025 | Tremfya |
| Incyte Corporation | $172.65 | 2023-2025 | Opzelura |
| Abbvie INC. | $135.57 | 2024-2025 | |
| Pfizer INC. | $88.94 | 2019-2022 | |
| Genzyme Corporation | $85.68 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $81.34 | 2019-2020 | |
| Almirall LLC | $66.30 | 2019-2025 | Seysara |
| Sun Pharmaceutical Industries INC. | $65.12 | 2019-2023 | Blu-U |
| Leo Pharma INC. | $55.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.71 | 2023 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $46.34 | 2023-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $40.16 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.69 | 2019 | |
| Dermira, INC. | $27.07 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $24.00 | 2019 | |
| Celgene Corporation | $23.77 | 2019 | |
| Ucb, INC. | $19.99 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $19.51 | 2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $19.29 | 2019 | |
| Epi Health, LLC | $18.87 | 2019 | |
| Novum Pharma, LLC | $17.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2025 | Sotyktu |
| Journey Medical Corporation | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laju Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.